SEARCH

SEARCH BY CITATION

References

  • 1
    Nolan CM, Beatty HN. Staphylococcus aureus bacteraemia: current clinical patterns. Am J Med 1976; 60: 495500.
  • 2
    Faber V, Jessen O, Rosendal K, Erikson KR. Staphylococcal bacteraemia: clinical and bacteriological observations in 201 cases. Br Med J 1960; ii: 18326.
  • 3
    Jessen O, Rosendal K, Bulow P, Faber V, Erikson KR. Changing staphylococci and staphylococcal infections. A ten year study of bacteria and cases of bacteraemia. N Engl J Med 1969; 281: 62735.
  • 4
    Gransden WR, Eykyn SJ, Phillips I. Staphylococcus aureus bacteraemia: 400 episodes in St Thomas's Hospital. Br Med J 1984; 288: 3003.
  • 5
    Mylotte JM, McDermott C, Spooner JA. Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteraemia. Rev Infect Dis 1987; 9(5): 891907.
  • 6
    Libman H, Arbeit RD. Complications associated with Staphylococcus aureus bacteremia. Arch Intern Med 1984; 144: 5415.
  • 7
    Musher DM, Lamm N, Darouiche RO, Young EJ, Hamill RJ, Landon GC. The current spectrum of Staphylococcus aureus infection in a tertiary care hospital. Medicine 1994; 73–4: 186208.
  • 8
    Jernigan JA, Farr BM. Short course therapy of catheter related Staphylococcus aureus bacteraemia: a meta analysis. Ann Intern Med 1993; 119(s4): 30411.
  • 9
    Lerner PI, Weinstein L. Infective endocarditis in the antibiotic era. N Engl J Med 1966; 274: 38893.
  • 10
    Hamburger M. Treatment of bacterial endocarditis. Mod Treat 1964; 1: 100315.
  • 11
    Mylotte JM, McDermott C, Spooner JA. Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteraemia. Rev Infect Dis 1987; 9(5): 891907.
  • 12
    Iannini PB, Crossley K. Therapy of Staphylococcus aureus bacteremia associated with a removable focus of infection. Ann Intern Med 1976; 84: 55860.
  • 13
    Ehni WF, Reller IB. Short course therapy for catheter associated Staphylococcus aureus bacteraemia. Arch Intern Med 1989; 149: 5336.
  • 14
    Torres-Tortosa M, Cueto M, Vergara A, et al. Prospective evaluation of a two week course of intravenous antibiotics in intravenous drug addicts with infective endocarditis. Eur J Clin Microbiol Infect Dis 1994; 13(7): 55964.
  • 15
    Raad II, Sabbagh MF. Optimal duration of therapy for catheter related Staphylococcus aureus bacteraemia: a study of 55 cases and review. Clin Infect Dis 1992; 14: 7582.
  • 16
    Sande MA, Scheld WM. Combination antibiotic therapy of bacterial endocarditis. Ann Intern Med 1980; 92: 3905.
  • 17
    Watanakunakorn C, Baird IM. Staphylococcus aureus bacteraemia and endocarditis associated with a removable infected intravenous device. Am J Med 1977; 63: 2536.
  • 18
    Mirimanoff RO, Glauser MP. Endocarditis during Staphylococcus aureus septicaemia in a population of non drug addicts. Arch Intern Med 1982; 42: 131113.
  • 19
    Bisno AL, Dismukes WE, Durack DT, et al. Antimicrobial treatment of infective endocarditis due to viridans streptococci, enterococci and staphylococci. JAMA 1989; 261(10): 14718.
  • 20
    Antibiotic treatment of streptococcal and staphylococcal endocarditis. Report of a working party of the British Society for Antimicrobial Chemotherapy. Lancet 326: 1985; 81517.
  • 21
    HawkeyPM, LewisDA (eds). Medical bacteriology. Oxford : Oxford University Press, 1989.
  • 22
    Working Party on Antibiotic Sensitivity Testing of the British Society for Antimicrobial Chemotherapy. A guide to sensitivity testing. J Antimicrob Chemother 1991; 27(suppl D).
  • 23
    Barrett N. Personal communication. Source: Communicable Disease Report Quarterly and Annual Tabulations 1983–1988; Oracle database (LabBase) 1989–1993; data unchecked.
  • 24
    Lautenschlager S, Herzog C, Zimmerli W. Course and outcome of bacteremia due to Staphylococcus aureus: evaluation of different clinical case definitions. Clin Infect Dis 1993; 16: 56773.
  • 25
    Waldvogel FA. Staphylococcus aureus (including toxic shock syndrome). In MandellGL, BennettJE, DolinR, eds. Mandell, Douglas and Bennett's Principles and practice of infectious diseases, 4th edn. Edinburgh : Churchill Livingstone, 1995: 175477.
  • 26
    Sande MA, Scheld WM. Combination antibiotic therapy of bacterial endocarditis. Ann Intern Med 1980; 92: 390.
  • 27
    Carbon C. Experimental endocarditis: a review of its relevance to human endocarditis. J Antimicrob Chemother 1993; 31(suppl D):S7185.
  • 28
    Mortara LA, Bayer AS. Staphylococcus aureus bacteraemia and endocarditis. Infect Dis Clin North Am 1993; 7(1): 5368.
  • 29
    Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and non-addicts—a prospective study. Ann Intern Med 1982; 97: 496503.
  • 30
    British National Formulary, No.29. London : British Medical Association and the Royal Pharmaceutical Society of Great Britain, 1995.
  • 31
    Faber M, Thamdrup Rosdahl V. Susceptibility to fusidic acid among Danish Staphylococcus aureus strains and fusidic acid consumption. J Antimicrob Chemother 1990; 25(suppl B): S714.
  • 32
    Eykyn SJ. Staphylococcal bacteremia with endocarditis and fusidic acid. J Antimicrob Chemother 1990; 25(suppl B): S338.
  • 33
    Coombs RRH. Fusidic acid in staphylococcal bone and joint infection. J Antimicrob Chemother 1990; 25(suppl B): S5360.
  • 34
    Cooper G, Platt R. Staphylococcus aureus bacteraemia in diabetic patients—endocarditis and mortality. Am J Med 1982; 73: 65862.